Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target... Interleukin-1 (IL-1) has long been known to be a key mediator of immunity and inflammation. Its dysregulation has been implicated in recent years in tumorigenesis and tumor progression, and its upregulation is thought to be associated with many tumors. Overexpression of the IL-1 agonists IL-1α and IL-1β has been shown to promote tumor invasiveness and metastasis by inducing the expression of angiogenic genes and growth factors. IL-1 blockers such as anakinra and canakinumab are already approved and widely used for the treatment of some autoimmune and autoinflammatory diseases and are currently being tested in preclinical and human clinical trials for cancer therapy. In this paper we review the most recent discoveries regarding the association between IL-1 dysregulation and cancer and present the novel IL-1 blockers currently being tested in cancer therapy and their corresponding clinical trials. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

Download PDF
19 pages

Loading next page...
 
/lp/springer-journals/the-role-of-interleukin-1-in-the-pathogenesis-of-cancer-and-its-5pjnVqGPQu
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0089-z
Publisher site
See Article on Publisher Site

Abstract

Interleukin-1 (IL-1) has long been known to be a key mediator of immunity and inflammation. Its dysregulation has been implicated in recent years in tumorigenesis and tumor progression, and its upregulation is thought to be associated with many tumors. Overexpression of the IL-1 agonists IL-1α and IL-1β has been shown to promote tumor invasiveness and metastasis by inducing the expression of angiogenic genes and growth factors. IL-1 blockers such as anakinra and canakinumab are already approved and widely used for the treatment of some autoimmune and autoinflammatory diseases and are currently being tested in preclinical and human clinical trials for cancer therapy. In this paper we review the most recent discoveries regarding the association between IL-1 dysregulation and cancer and present the novel IL-1 blockers currently being tested in cancer therapy and their corresponding clinical trials.

Journal

Oncology and Therapy – Springer Journals

Published: Nov 28, 2018

References

  • Infection and inflammation: impacts on oncogenesis
    Schmidt, A; Weber, OF
  • Inflammation and cancer: an ancient link with novel potentials
    Hussain, SP; Harris, CC
  • Cytokines as a key component of cancer-related inflammation
    Germano, G; Allavena, P; Mantovani, A
  • Origin and physiological roles of inflammation
    Medzhitov, R
  • The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer?
    Escamilla-Tilch, M; Filio-Rodriguez, G; Garcia-Rocha, R
  • Role of nonresolving inflammation in hepatocellular carcinoma development and progression
    Yu, LX; Ling, Y; Wang, HY
  • Hallmarks of cancer: the next generation
    Hanahan, D; Weinberg, RA
  • Chronic inflammation and cytokines in the tumor microenvironment
    Landskron, G; Fuente, M; Thuwajit, P; Thuwajit, C; Hermoso, MA
  • Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota
    Jess, T; Loftus, EV; Velayos, FS
  • Mechanisms of the combined effect of asbestos and smoking in the etiology of lung cancer
    Vainio, H; Boffetta, P
  • Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer
    Yoshida, T; Kato, J; Inoue, I
  • Bacterial DNA sequences in prostate tissue from patients with prostate cancer and chronic prostatitis
    Kriger, JN; Riley, DE; Vessela, RL; Miner, DC; Ross, SO; Lange, PH
  • Epidemiology of viral hepatitis and hepatocellular carcinoma
    El-Serag, HB
  • The human papillomavirus (HPV)-related cancer biology: an overview
    Araldi, RP; Sant’Ana, TA; Modolo, DG
  • Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment
    Lewis, AM; Varghese, S; Xu, H; Alexander, HR
  • IL-1 is required for tumor invasiveness and angiogenesis
    Voronov, E; Shouval, DS; Krelin, Y
  • DNA damage talks to inflammation
    Cohen, I
  • The interleukin-1 family: back to the future
    Garlanda, C; Dinarello, CA; Mantovani, A
  • Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors
    Krelin, Y; Voronov, E; Dotan, S
  • Chromosomal localization of the human interleukin 1 alpha (IL-1 alpha) gene
    Modi, WS; Masuda, A; Yamada, M; Oppenheim, JJ; Matsushima, K; O’Brien, SJ
  • Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1α
    Kobayashi, Y; Yamamoto, K; Saido, T; Kawasaki, H; Oppenheim, JJ; Matsushima, K
  • The family of the interleukin-1 receptors
    Boraschi, D; Italiani, P; Weil, S; Martin, MU
  • Interleukin-1α
    Rider, P; Carmi, Y; Voronov, E; Apte, RN
  • An expanding role for interleukin-1 blockade from gout to cancer
    Dinarello, CA
  • Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
    Dinarello, CA; Simon, A; Meer, JW
  • IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity
    Cohen, I; Rider, P; Vornov, E
  • Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation
    Cohen, I; Rider, P; Carmi, Y
  • Alarmins: feel the stress
    Rider, P; Voronov, E; Dinarello, CA; Apte, RN; Cohen, I
  • Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs of the immune system
    Martin, SJ
  • A critical role for interleukin-1β in the progression of autoimmune diseases
    Zhao, R; Zhou, H; Bo, SuS
  • Interleukin-1β promotes the induction of retinal autoimmune disease
    Zhao, R; Zhou, H; Zhang, J; Liu, X; Bo, SuS
  • A clinical perspective of IL-1b as the gatekeeper of inflammation
    Dinarello, CA
  • Interleukin-1: Ariadne’s thread in autoinflammatory and autoimmune disorders
    Cantarini, L; Lopalco, G; Cattalini, M; Vitale, A; Galeazzi, M; Rigante, D
  • Inflammasome-independent regulation of IL-1-family cytokines
    Netea, MG; Veerdonk, FL; Meer, JWM; Dinarello, CA; Joosten, LAB
  • A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist
    Scheuder, H; Tardif, C; Trump-kallmeyer, S
  • The balance between IL-1 and IL-1Ra in disease
    Arend, WP
  • Interleukin-1 receptor antagonist: role in biology
    Arend, WP; Malyak, M; Guthridge, CJ; Gabay, C
  • The interleukin (IL)-1 cytokine family—balance between agonists and antagonists in inflammatory diseases
    Palomo, J; Dietrich, D; Martin, P; Palmer, G; Gabay, C
  • Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis
    Fang, XM; Schroder, S; Hoeft, A; Stuber, F
  • An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist
    Aksentijevich, I; Masters, SL; Ferguson, PJ
  • An autoinflammatory disease due to homozygous deletion of the IL1RN locus
    Reddy, S; Jia, S; Geoffrey, R
  • IL-1 receptor 2 (IL-1R2) and its role in immune regulation
    Peters, VA; Joesting, JJ; Freund, GG
  • The interleukin-1 receptor family
    Boraschi, D; Tagliabue, A
  • Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist
    Symons, JA; Young, PR; Duff, GW
  • Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8
    Molgora, M; Supino, D; Mantovani, A; Garlanda, C
  • Purification and characterization of a novel soluble receptor for interleukin 1
    Symons, JA; Eastgate, JA; Duff, GW
  • The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action
    Smith, DE; Hanna, R; Friend, D
  • Cancer-related inflammation
    Mantovani, A; Allavena, P; Sica, A; Balkwill, F
  • IL-1 and IL-1 regulatory pathways in cancer progression and therapy
    Mantovani, A; Barajon, I; Garlanda, C
  • Aberrant expression of interleukin-1b and inflammasome activation in human malignant gliomas
    Tarassishin, L; Casper, D; Lee, SC
  • IL-1b microenvironment promotes proliferation, migration and invasion of human glioma cells
    Hurmath, KF; Ramaswamy, P; Nandakumar, DN
  • NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/NF-κB p65 signals
    Xue, L; Lu, B; Gao, B
  • Hepatocyte growth factor and Met in drug discovery
    Sakai, K; Aoki, S; Matsumoto, K
  • Met, metastasis, motility and more
    Birchmeier, C; Birchmeier, W; Gherardi, E; Vande Woude, GF
  • Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κB pathway in human colon cancer cell
    Ma, J; Sun, X; Guo, T
  • Cyst fluid interleukin-1b (IL1b) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas
    Maker, AV; Katabi, N; Qin, LX
  • NFkB-mediated invasiveness in CD133+ pancreatic TICs is regulated by autocrine and paracrine activation of IL-1 signaling
    Nomura, A; Gupta, VK; Dauer, P
  • Inflammasomes in liver diseases
    Szabo, G; Csak, T
  • Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
    Yoshimoto, S; Loo, TM; Atarashi, K
  • Interleukin-1β/interleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent gankyrin activation during hepatocarcinogenesis
    Su, B; Luo, T; Zhu, J
  • Role of interleukin 1 beta in esophageal squamous cell carcinoma
    Chen, MF; Lu, MS; Chen, PT; Chen, WC; Lin, PY; Lee, KD
  • Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer
    Yigit, M; Değirmencioğlu, S; Ugurlu, E; Yaren, A
  • TAp73 upregulates IL-1β in cancer cells: potential biomarker in lung and breast cancer?
    Vikhreva, P; Petrova, V; Gokbulut, T
  • The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer
    Al-Sahaf, S; Hunter, KD; Bolt, R; Ottewell, PD; Murdoch, C
  • Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
    Stanam, A; Gibson-Corley, KN; Love-Homan, L; Ihejirika, N; Simons, AL
  • IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer
    Wu, TC; Xu, K; Martinek, J
  • An interleukin-1 signature in breast cancer treated with interleukin-1 receptor blockade: implications for treating cytokine release syndrome of checkpoint inhibitors
    Dinarello, CA
  • IL-1 drives breast cancer growth and bone metastasis in vivo
    Holen, I; Lefley, DV; Francis, SE
  • The role of interleukin-1 in inflammatory and malignant human skin diseases and the rationale for targeting interleukin-1 alpha
    Bou-Dargham, MJ; Khamis, ZI; Cognetta, AB; Sang, QA
  • IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis
    Mehtap, O; Atesoglu, EB; Tarkun, P; Hacihanefioglu, A; Dolasik, I; Musul, MM
  • Elevation of serum interleukins 8, 4, and 1β levels in patients with gastrointestinal low-grade B-cell lymphoma
    Miyata-Takata, T; Takata, K; Toji, T
  • Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma
    Wang, Y; Wang, Y; Duan, X; Wang, Y; Zhang, Z
  • Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts
    Schauer, IG; Zhang, J; Xing, Z
  • The role of tumor necrosis factor-alpha and interleukin-1 in the mammalian testis and their involvement in testicular torsion and autoimmune orchitis
    Lysiak, JJ
  • Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals
    Tao, L; Qiu, J; Slavin, S
  • Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer
    Yang, DR; Ding, XF; Luo, J
  • Interleukin 1 gene polymorphism and susceptibility to disease
    Khazim, K; Azulay, EE; Kristal, B; Cohen, I
  • Interleukin 1β and interleukin 1 receptor antagonist gene polymorphisms and cervical cancer: a meta-analysis
    Wu, S; Hu, G; Chen, J; Xie, G
  • Common variants in IL-1RN, IL-1β and TNF-α and the risk of ovarian cancer: a case control study
    Ahmed, AB; Zidi, S; Sghaier, I
  • A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma
    Vangsted, AJ; Nielsen, KR; Klausen, TW; Haukaas, E; Tjønneland, A; Vogel, U
  • Potential influence of interleukin-1 haplotype IL-1 beta-511*T-IL-1RN*1 in conferring low risk to middle third location of esophageal cancer: a case-control study
    Upadhyay, R; Jain, M; Kumar, S; Ghoshal, UC; Mittal, B
  • Association between the IFN-γ and IL-1 genetic polymorphisms and colorectal cancer in the Chinese Han population
    Fei, BY; Lv, HX; Cheng, YW; Yang, JM
  • Association of interleukin 1 beta (IL-1β) polymorphism with mRNA expression and risk of non-small cell lung cancer
    Bhat, IA; Naykoo, NA; Qasim, I
  • Interleukin 1 beta gene promoter SNPs are associated with risk of pancreatic cancer
    Hamacher, R; Diersch, S; Scheibel, M
  • Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk
    Xu, H; Ding, Q; Jiang, HW
  • Associations of Il-1 family-related polymorphisms with gastric cancer risk and the role of Mir-197 in Il-1f5 expression
    Chen, X; Xu, Y; Cao, X; Chen, Y; Jiang, J; Wang, K
  • Combination of interleukin 1 polymorphism and Helicobacter pylori infection: an increased risk of gastric cancer in Pakistani population
    Raza, Y; Khan, A; Khan, AI
  • Association of Interleukin-1 beta and tumor necrosis factor-alpha genetic polymorphisms with gastric cancer in India
    Sultana, Z; Bankura, B; Pattanayak, AK
  • Biologics for targeting inflammatory cytokines, clinical uses, and limitations
    Rider, P; Carmi, Y; Cohen, I
  • MABp1, a first-in-class True Human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
    Hong, DS; Hui, D; Bruera, E
  • Xilonix, a novel True Human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
    Hong, DS; Janku, F; Naing, A
  • A phase III study of Xilonix in refractory colorectal cancer patients with weight loss
    Fisher, GA
  • MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
    Hickish, T; Andre, T; Wyrwicz, L
  • The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β
    Rondeau, JM; Ramage, P; Zurini, M; Gram, H
  • Antiinflammatory therapy with canakinumab for atherosclerotic disease
    Ridker, PM; Everett, BM; Thuren, T
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
    Ridker, PM; MacFadyen, JG; Thuren, T
  • A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy
    Goh, AX; Bertin-Maghit, S; Ping Yeo, S
  • Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1
    Xiong, Y; Donovan, KA; Kline, MP
  • Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component
    Lust, JA; Lacy, MQ; Zeldenrust, SR
  • Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma
    Lust, JA; Lacy, MQ; Zeldenrust, SR
  • Phase I/II study of IP-1510 a novel interleukin-1 receptor antagonist in the management of cancer-related cachexia
    Paspaliaris, V; Langan, B; DeAndrea, R; Wood, J; Tsouvelekas, A; Demosthenes, B